CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This activity is intended for medical oncologists, breast surgeons, radiation oncologists and other healthcare professionals involved in the diagnosis and treatment of breast cancer (BC).
  
  OVERVIEW OF ACTIVITY
  The long-term management of early and advanced HER2-positive BC has been in a constant state of evolution over the past several years. A number of relevant clinical and regulatory developments coupled with many lingering practical management concerns and the activation of a multitude of clinical trials evaluating novel agents have challenged physicians and their support staffs as they attempt to deliver state-of-the-art care for this distinct patient population.
  
  These video proceedings from a CME symposium during the San Antonio Breast Cancer Symposium feature discussions with leading researchers with an expertise in BC regarding actual cases from their practices and the published data that drive clinical decision-making for patients in those and diverse other situations. By providing information on the latest research developments and their potential application to routine practice, this activity is designed to assist medical oncologists and other healthcare professionals with the formulation of up-to-date clinical management strategies.
  
  LEARNING OBJECTIVES
  

  • Appreciate the key clinical variables that affect the use of preoperative therapy and the selection of specific therapeutic regimens for patients with HER2-overexpressing localized BC, and integrate this information into current treatment decision-making.
  • Apply emerging research evidence to individualize the selection and use of adjuvant systemic therapy for patients with HER2-positive localized BC who have previously received neoadjuvant treatment.
  • Evaluate published research data to guide the selection and duration of adjuvant and/or extended-adjuvant therapy for patients with HER2-overexpressing localized BC.
  • Implement a long-term clinical plan for the management of advanced HER2-positive BC, incorporating existing and emerging targeted treatments.
  • Design an optimal approach to the clinical care of patients with HER2-positive BC and CNS metastases, considering the implications of prior therapeutic exposure, symptomatology and other relevant factors.
  • Develop an understanding of the mechanism of action of and pivotal clinical trial findings with tucatinib in combination with trastuzumab and capecitabine for patients with previously treated HER2-positive BC in preparation for the potential availability of this novel compound.
  • Appraise available research data and ongoing clinical trials evaluating trastuzumab deruxtecan for HER2-positive BC, consider its potential role in clinical practice and counsel appropriately selected patients about participation in research protocols.
  • Assess ongoing clinical research studies evaluating novel agents and treatment strategies under development for metastatic HER2-positive BC, and counsel patients regarding the potential benefits of trial participation.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  CME credit is no longer available for this issue
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  CME credit is no longer available for this issue
  
  HOW TO USE THESE CME ACTIVITIES
  This CME activity consists of a video component.
  CME credit is no longer available for this issue
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:
  
  Adam M Brufsky, MD, PhD
  Professor of Medicine
  Co-Director, Comprehensive Breast Cancer Center
  UPMC Hillman Cancer Center
  Associate Division Chief, Division of Hematology/Oncology
  Department of Medicine
  University of Pittsburgh
  Pittsburgh, Pennsylvania
  
  Consulting Agreements: Agendia Inc, Amgen Inc, AstraZeneca Pharmaceuticals LP, bioTheranostics Inc, Celgene Corporation, Daiichi Sankyo Inc, Eisai Inc, Genentech, Lilly, Novartis, Pfizer Inc, Puma Biotechnology Inc, Sandoz Inc, a Novartis Division.
  
  Lisa A Carey, MD
  Richardson and Marilyn Jacobs Preyer Distinguished Professor for Breast Cancer Research
  Chief, Division of Hematology and Oncology
  Physician-in-Chief
  North Carolina Cancer Hospital
  Associate Director for Clinical Research
  Lineberger Comprehensive Cancer Center
  Chapel Hill, North Carolina
  
  No relevant conflicts of interest to disclose.
  
  Sara Hurvitz, MD
  Associate Professor of Medicine
  David Geffen School of Medicine at UCLA
  Director, Breast Cancer Clinical Research Program
  Co-Director, Santa Monica-UCLA Outpatient Oncology Practice
  Santa Monica, California
  
  Grant/Support: Ambryx Inc, Amgen Inc, Bayer HealthCare Pharmaceuticals, BioMarin, Boehringer Ingelheim Pharmaceuticals Inc, Daiichi Sankyo Inc, Dignitana, Genentech, GlaxoSmithKline, Lilly, MacroGenics Inc, Medivation Inc, a Pfizer Company, Merrimack Pharmaceuticals Inc, Novartis, OBI Pharma Inc, Pfizer Inc, Pieris Pharmaceuticals, Puma Biotechnology Inc, Roche Laboratories Inc, Seattle Genetics; Paid Travel: Lilly, Novartis, OBI Pharma Inc.
  
  Martine J Piccart-Gebhart, MD, PhD
  Scientific Director
  Jules Bordet Institute
  Université Libre de Bruxelles
  Brussels, Belgium
  
  Advisory Committee and Scientific Boards: Oncolytics Biotech Inc, Radius Health Inc; Consulting Agreements: AstraZeneca Pharmaceuticals LP, Camel-IDS, Crescendo Biologics, Debiopharm Group, G1 Therapeutics, Genentech, HUYA Bioscience International, Immunomedics Inc, Lilly, Menarini Group, Merck Sharp & Dohme Corp, Novartis, Odonate Therapeutics, PeriphaGen Inc, Pfizer Inc, Roche Laboratories Inc, Seattle Genetics; Contracted Research: AstraZeneca Pharmaceuticals LP, Genentech, Lilly, Merck Sharp & Dohme Corp, Novartis, Pfizer Inc, Radius Health Inc, Roche Laboratories Inc, Servier, Synthon.
  
  MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Ariad Pharmaceuticals Inc, Array BioPharma Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Exelixis Inc, Foundation Medicine, Genentech, Genmab, Genomic Health Inc, Gilead Sciences Inc, Guardant Health, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite Pharma Inc, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seattle Genetics, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc and Tolero Pharmaceuticals.
  
  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  This activity is supported by educational grants from Daiichi Sankyo Inc, Genentech, Puma Biotechnology Inc and Seattle Genetics.
  
  Hardware/Software Requirements:
  A high-speed Internet connection
  A monitor set to 1280 x 1024 pixels or more
  Internet Explorer 11 or later, Firefox 56 or later, Chrome 61 or later, Safari 11 or later, Opera 48 or later
  Adobe Flash Player 27 plug-in or later
  Adobe Acrobat Reader
  (Optional) Sound card and speakers for audio
  
  Release date: March 2020
  Expiration date: March 2021